For pathologists staring down mountains of tissue slides every week, the promise of artificial intelligence has always been simple: catch what tired human eyes might miss. Now that promise has cleared a major regulatory hurdle. Paige, the digital pathology company that made history in 2021 as the first vendor to win FDA clearance for an AI-based pathology product, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration for a new tool called PanCancer Detect.
What PanCancer Detect Actually Does
Unlike Paige’s earlier product, Paige Prostate, which was trained specifically to flag suspicious regions in prostate biopsies, PanCancer Detect is designed to work across multiple anatomic sites and tissue types. The software scans digitized biopsy slides and highlights foci that are suspicious for cancer, whether common or rare, giving pathologists a second set of eyes before they render a diagnosis. The FDA’s Breakthrough Device pathway is reserved for technologies that could offer more effective diagnosis of life-threatening conditions, and it grants companies faster, more interactive review during the approval process.
The Numbers Behind the Breakthrough
In clinical validation testing cited by Paige, the AI-assisted workflow improved cancer detection by an average of 7.3 percent compared with unassisted pathologist reads, pushing accuracy from roughly 89.5 percent to 96.8 percent. Just as notable, the tool reportedly cut false negatives by 70 percent and reduced false positives by 24 percent. For a field where a missed malignancy can mean a delayed diagnosis and a false positive can trigger unnecessary anxiety and follow-up procedures, those margins matter enormously to both patients and health systems trying to control costs.
From Paige Prostate to Tempus
Paige’s journey traces the broader arc of AI in pathology. The company’s original product, Paige Prostate, became the first and only AI-based pathology device to receive FDA clearance for in vitro diagnostic use in detecting cancer in prostate biopsies back in 2021. That milestone opened the door for a wave of digital pathology startups. In 2024, Paige was acquired by Tempus, the Chicago-based precision medicine and AI company built by David Jones and Eric Lefkofsky, folding Paige’s imaging expertise into Tempus’s broader genomic and clinical data platform. PanCancer Detect represents the most ambitious product to emerge from that combined pipeline so far.
Two Views From the Field
Supporters argue tools like PanCancer Detect are essential as pathology departments face rising caseloads, workforce shortages, and mounting turnaround-time pressure. Proponents say an AI second reader can help generalist pathologists catch rare cancer patterns they may see only a handful of times in a career, effectively democratizing subspecialist-level scrutiny for hospitals that cannot afford to keep every kind of specialist on staff. Skeptics, however, caution that expanding an AI system from a single, well-studied cancer type to dozens of anatomic sites multiplies the risk of edge cases and dataset bias. Pathology groups have also raised concerns about liability: if an AI model misses a rare cancer subtype underrepresented in its training data, questions remain about who bears responsibility, the software vendor or the reviewing physician of record.
Regulatory Backdrop
The designation arrives as the FDA has also updated broader guidance for clinical decision support software, in some cases relaxing device requirements so that generative AI diagnostic tools can reach clinics with less upfront vetting. At the same time, state legislatures in at least five states have introduced bills this year aimed at requiring human review of AI-assisted decisions in health care, particularly around insurance denials, reflecting a policy environment that is simultaneously accelerating AI adoption and trying to build guardrails around it.
What’s Next
Breakthrough Device designation does not equal final market clearance; it means the FDA will work more closely and quickly with Paige as the company compiles data for a formal submission. Analysts covering the digital pathology market, which multiple industry reports peg for double-digit annual growth through the early 2030s, expect Paige to pursue clearance site by site, tissue type by tissue type, rather than seeking one sweeping approval. For hospitals and diagnostic labs already straining under delayed turnaround times and uneven access to subspecialists, the next milestone to watch will be whether PanCancer Detect earns full clearance and how quickly community hospitals, not just major academic medical centers, are able to afford and adopt it.
Photo: cocoandwifi / PIXABAY via Pixabay
